MOTS c () 40mg research peptide vial - MOTS c () peptide for laboratory research - Shrine Peptides MOTS-c (40mg) $272.00
GHK Cu () 50mg research peptide vial - GHK Cu () peptide for laboratory research - Shrine Peptides GHK-Cu (50mg) $51.00

Selank (11mg)

$46.00

Selank (11mg) – Research grade peptide for laboratory investigations and preclinical studies | Research Use Only – Not for Human Consumption

Fast shipping to all 50 states

  • 99.8% Pure – Lab Verified
  • GMP Certified
  • COA Available
Add to Cart
Selank () 11mg research peptide vial - Selank () peptide for laboratory research - Shrine Peptides
Selank (11mg)
$46.00
Guaranteed Safe Checkout

Guaranteed Safe Checkout

Selank (11mg) Research Compound

Research Use Only – Not for Human or Animal Consumption

Selank (11mg) is a synthetic research peptide that has been investigated in laboratory settings for its potential interactions with various biological pathways. This research compound has been studied in preclinical models to evaluate its pharmacological properties and potential mechanisms of action.1 Preliminary investigations have examined this peptide’s effects on cellular signaling pathways, receptor interactions, and physiological responses in controlled laboratory environments.

Research Overview

Laboratory studies have explored the potential biological activities of Selank (11mg) through various experimental methodologies. Research has focused on characterizing the peptide’s structure-activity relationships, binding affinities to target receptors, and downstream signaling cascade activation.2 Preclinical investigations have utilized multiple research models to assess the compound’s pharmacokinetic properties, including absorption, distribution, metabolism, and elimination characteristics. These fundamental research efforts contribute to the broader understanding of peptide-based signaling mechanisms and their potential applications in biological research.

Preclinical Investigations

Research teams have conducted systematic investigations to evaluate Selank (11mg)’s biological activities in controlled experimental settings. Studies have employed various in vitro and in vivo methodologies to assess the peptide’s effects on cellular processes, tissue function, and systemic responses in research models.3 Data from these investigations have contributed to understanding the peptide’s potential mechanisms of action, optimal dosing parameters for research applications, and potential interactions with biological systems.

Product Specifications

  • Contents: Selank (11mg)
  • Form: Lyophilized powder
  • Purity: >98% (verified by HPLC)
  • Storage: Store at -20°C in a dry environment
  • Reconstitution: Use bacteriostatic water for laboratory applications
  • Stability: Stable when stored properly under recommended conditions

Quality Assurance and Documentation

  • Third-party laboratory tested for purity and identity verification
  • Certificate of Analysis (COA) available upon request for each batch
  • HPLC chromatography results provided
  • Mass spectrometry data available
  • Manufactured under strict quality control protocols
  • Batch-specific documentation and traceability
  • Compliance with research-grade standards

Research Applications

  • Peptide receptor interaction studies
  • Cellular signaling pathway research
  • Pharmacokinetic and pharmacodynamic investigations
  • Structure-activity relationship studies
  • Preclinical model research
  • Biochemical pathway mapping
  • Molecular mechanism elucidation
  • In vitro biological activity screening
  • Peptide stability and formulation research
  • Comparative peptide pharmacology studies

Important Research Notice

FOR LABORATORY AND RESEARCH USE ONLY. This product is intended exclusively for scientific research, in vitro studies, and laboratory investigations. This compound is not intended for human or animal consumption, clinical applications, or any diagnostic or therapeutic uses.

Researchers should consult relevant scientific literature and follow appropriate safety protocols when handling this research compound. Proper laboratory equipment, personal protective equipment, and training are required for working with this material.

Regulatory Compliance Statement

This product is sold as a research chemical for laboratory use only. Shrine Peptides operates as a chemical supplier. Shrine Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Shrine Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

The statements made within this product description have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure or prevent any disease. Human/Animal Consumption Prohibited. Laboratory/In-Vitro Experimental Use Only.

Please review and adhere to our Terms and Conditions before ordering.

References:

  1. Inozemtseva, L. S., Karpenko, E. A., Dolotov, O. V., Levitskaya, N. G., Kamensky, A. A., Andreeva, L. A., & Grivennikov, I. A. (2008). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 421, 241–243. https://doi.org/10.1134/s0012496608040066
  2. Najjar VA. Tuftsin, a natural activator of phagocyte cells: an overview. Ann N Y Acad Sci. 1983;419:1-11. doi: 10.1111/j.1749-6632.1983.tb37086.x. https://pubmed.ncbi.nlm.nih.gov/6370072/
  3. Semenova, T. P., kozlovskiĭ, I. I., Zakharova, N. M., & Kozlovskaia, M. M. (2009). Eksperimental’naia i klinicheskaia farmakologiia, 72(4), 6–8.
  4. Fridkin M, Stabinsky Y, Zakuth V, Spirer Z. Tuftsin and some analogs: synthesis and interaction with human polymorphonuclear leukocytes. Biochim Biophys Acta. 1977 Jan 24;496(1):203-11. https://pubmed.ncbi.nlm.nih.gov/576412/
  5. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003 Nov;33(9):853-60. https://pubmed.ncbi.nlm.nih.gov/14969422/
  6. Elena Filatova et al., GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. https://doi.org/10.3389/fphar.2017.00089
  7. Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in pharmacology, 7, 31. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757669/
  8. T.A Kolomin et al., Transcriptomic Response of Rat Hippocampus and Spleen Cells to Single and Chronic Administration of the Peptide Selank. June 2, 2009. DOI: 10.1134/S1607672910010023
  9. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. Russian. https://pubmed.ncbi.nlm.nih.gov/18454096/
  10. Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. Russian. https://pubmed.ncbi.nlm.nih.gov/25176261/
  11. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003 Sep;33(7):639-43. https://pubmed.ncbi.nlm.nih.gov/14552529/
  12. Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. Russian. https://pubmed.ncbi.nlm.nih.gov/18577961/
  13. Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014 May;157(1):52-5. https://pubmed.ncbi.nlm.nih.gov/24913576/
  14. Gan’shina TS, Kozlovskiĭ II. [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]. Eksp Klin Farmakol. 2005 Jul-Aug;68(4):33-5. Russian. https://pubmed.ncbi.nlm.nih.gov/16193654/
  15. N.F. Mjasoedov et al, The Influence of Selank on the Parameters of the Hemostasis System, Lipid Profile, and Blood Sugar Level in the Course of Experimental Metabolic Syndrome. April 14, 2014.

Related Research Peptides

Browse by Category

Related Research Peptides

Browse by Category

SKU: YPB.228 Category:

Related products